JDQ443 (Not yet branded)
Other Medications
Description
JDQ443 is a selective KRAS G12C inhibitor designed to target colorectal cancers harboring the specific KRAS G12C mutation. This compound represents a novel approach to treating CRC patients whose tumors carry this particular mutation, which occurs in approximately 3-5% of colorectal cancer cases. The drug functions as a covalent inhibitor that specifically binds to the mutated KRAS protein in its inactive GDP-bound state.
Mechanism of Action
JDQ443 works by covalently binding to the cysteine residue unique to the KRAS G12C mutant protein, effectively trapping it in its inactive conformation. This prevents the mutant KRAS from cycling to its active GTP-bound state, thereby blocking downstream signaling pathways including RAF-MEK-ERK and PI3K-AKT that drive tumor cell proliferation and survival.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
 Estado EMA | Experimental |
 Acceso España | med_spain_not_available |
| Administration | Oral |
| Clinical Trials | 2 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.